Robert I. Haddad
#153,436
Most Influential Person Now
Robert I. Haddad's AcademicInfluence.com Rankings
Robert I. Haddadphilosophy Degrees
Philosophy
#8574
World Rank
#11982
Historical Rank
Logic
#5607
World Rank
#7018
Historical Rank
Robert I. Haddadbiology Degrees
Biology
#11637
World Rank
#15047
Historical Rank
Genetics
#1265
World Rank
#1367
Historical Rank
Download Badge
Philosophy Biology
Robert I. Haddad's Degrees
- Doctorate Medicine Harvard University
Why Is Robert I. Haddad Influential?
(Suggest an Edit or Addition)Robert I. Haddad's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. (2016) (1900)
- Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. (2007) (1535)
- Recent advances in head and neck cancer. (2008) (880)
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort (2016) (651)
- Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. (2013) (567)
- Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. (2018) (477)
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. (2017) (457)
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (454)
- Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. (2011) (437)
- NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. (2018) (381)
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. (2011) (352)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. (2015) (335)
- Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients (2009) (297)
- Characterization of HPV and host genome interactions in primary head and neck cancers (2014) (296)
- NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. (2017) (285)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018) (277)
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. (2017) (276)
- Response and acquired resistance to everolimus in anaplastic thyroid cancer. (2014) (264)
- Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. (2010) (243)
- Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. (2008) (224)
- Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma (2015) (221)
- Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. (2003) (216)
- A phase II study of gefitinib in patients with advanced thyroid cancer. (2007) (210)
- NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. (2018) (200)
- Radiation treatment breaks and ulcerative mucositis in head and neck cancer. (2008) (191)
- Head and Neck Cancers, Version 1.2015. (2015) (186)
- HER2 Expression in Salivary Gland Carcinomas (2004) (183)
- Head and neck cancers: Clinical practice guidelines in oncology (2011) (178)
- Thyroid carcinoma, version 2.2014. (2014) (176)
- Frameshift events predict anti-PD-1/L1 response in head and neck cancer. (2018) (173)
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. (2020) (172)
- NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. (2022) (165)
- Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. (2013) (161)
- Trastuzumab for the treatment of salivary duct carcinoma. (2013) (150)
- Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. (2014) (148)
- Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. (2013) (147)
- Head and Neck Cancers, Version 2.2014 (2014) (145)
- Biomarkers of HPV in head and neck squamous cell carcinoma. (2012) (138)
- Small-cell carcinoma of the lung: derivation of a prognostic staging system. (1991) (138)
- Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. (2009) (138)
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (2021) (136)
- Head and Neck Cancers, Version 2.2013 (2013) (132)
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. (2020) (130)
- Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck (2016) (128)
- Marital status and head and neck cancer outcomes (2015) (122)
- Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. (2014) (114)
- Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. (2015) (112)
- Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. (2005) (107)
- Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. (2012) (106)
- The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. (2016) (100)
- Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes (2011) (100)
- Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (2003) (100)
- Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States (2019) (98)
- Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. (2021) (96)
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (2019) (95)
- Positron emission tomography with 18F‐fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer (2004) (95)
- Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. (2007) (94)
- Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy (2013) (93)
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial (2020) (91)
- Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer (2006) (86)
- Anaplastic Thyroid Carcinoma, Version 2.2015. (2015) (85)
- Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. (2015) (83)
- Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer (2009) (82)
- Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions (2018) (81)
- Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. (2009) (81)
- Efficacy and toxicity of reirradiation using intensity‐modulated radiotherapy for recurrent or second primary head and neck cancer (2010) (79)
- Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. (1993) (79)
- Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes (2017) (78)
- Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. (2006) (78)
- Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. (2014) (78)
- Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. (2004) (75)
- Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. (2012) (74)
- Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer (2018) (74)
- Second primary malignancies following diagnosis of small-cell lung cancer. (1992) (72)
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. (2012) (70)
- An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients (2019) (69)
- Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes (2016) (68)
- Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial (2018) (68)
- Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study (2018) (68)
- Vandetanib for the Treatment of Medullary Thyroid Cancer (2012) (68)
- Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer (2011) (66)
- beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. (2009) (64)
- Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer (2017) (64)
- CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. (2018) (63)
- Head and neck cancer (2021) (63)
- Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. (2011) (62)
- Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer (2016) (62)
- Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer (2004) (62)
- Chemoradiotherapy for Adenoid Cystic Carcinoma: Preliminary Results of an Organ Sparing Approach (2006) (59)
- Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. (2003) (57)
- Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial (2019) (56)
- Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. (2009) (56)
- Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. (2005) (56)
- Patient‐reported receipt of and interest in smoking‐cessation interventions after a diagnosis of cancer (2011) (55)
- Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. (2010) (54)
- A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). (2013) (53)
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations (2021) (53)
- Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. (2016) (52)
- Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck (2001) (51)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. (2016) (50)
- Erythropoietin to treat anaemia in patients with head and neck cancer (2004) (48)
- Management of elderly patients with locoregionally confined head and neck cancer. (2017) (48)
- Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. (2011) (47)
- Organ Preservation and Treatment Toxicity With Induction Chemotherapy Followed by Radiation Therapy or Chemoradiation for Advanced Laryngeal Cancer (2005) (47)
- Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. (2011) (47)
- Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma (2016) (47)
- Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). (2017) (45)
- Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. (2017) (44)
- 910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) (2020) (42)
- A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck (2004) (42)
- The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). (2012) (42)
- Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. (2012) (42)
- Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. (2007) (41)
- Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma (2019) (41)
- Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 (2016) (41)
- Management of treatment-related toxicities in advanced medullary thyroid cancer. (2018) (40)
- Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study (2020) (39)
- HPV16 transmission between a couple with HPV-related head and neck cancer. (2008) (39)
- Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors (2020) (38)
- Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy (2022) (38)
- Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial† (2016) (38)
- Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. (2010) (38)
- Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC) (2018) (37)
- Thyroid carcinoma. (2010) (36)
- A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer (2008) (35)
- Multidisciplinary approach to cancer treatment: focus on head and neck cancer. (2008) (35)
- Combined antegrade and retrograde esophageal dilation for head and neck cancer‐related complete esophageal stenosis (2010) (35)
- Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer (2017) (33)
- Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer: A Case Series Report (2010) (33)
- Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium (2016) (33)
- Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. (2015) (33)
- 1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes (2017) (32)
- Chemoradiation‐Induced Cell Loss in Human Submandibular Glands (2005) (32)
- EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2019) (31)
- Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. (2006) (31)
- Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2016) (31)
- Medullary carcinoma: Clinical practice guidelines in oncology™ (2010) (31)
- The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana‐Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline (2017) (31)
- The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. (2017) (30)
- Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck (2003) (29)
- Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. (2019) (28)
- Novel biomarker panel predicts prognosis in human papillomavirus‐negative oropharyngeal cancer (2012) (28)
- Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? (2013) (28)
- Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck (2021) (27)
- Medullary carcinoma. (2010) (27)
- Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial (2020) (26)
- Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. (2017) (26)
- Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. (2017) (26)
- Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Therapy: A Case Series. (2020) (26)
- Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. (2018) (25)
- Barriers to clinical trial recruitment in head and neck cancer. (2015) (25)
- Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer (2019) (25)
- CDKN2A Alterations and Response to Immunotherapy in Solid Tumors (2021) (24)
- The effects of somatostatin and octreotide on experimental and human acute pancreatitis. (2000) (24)
- Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment (2013) (24)
- A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions (2008) (24)
- Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. (2006) (24)
- Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. (2019) (24)
- Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. (2012) (24)
- Swallowing Function following Postchemoradiotherapy Neck Dissection (2011) (23)
- Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? (2008) (23)
- Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. (2020) (23)
- The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. (2020) (22)
- A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651 (2016) (22)
- Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). (2016) (22)
- A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). (2020) (21)
- Photodynamic therapy of cancer of the esophagus using systemic aminolevulinic acid and a non laser light source: a phase I/II study. (1999) (21)
- Photodynamic therapy of murine colon cancer and melanoma using systemic aminolevulinic acid as a photosensitizer. (2000) (21)
- Behavior of oral squamous cell carcinoma in subjects with prior lichen planus (2007) (21)
- Everolimus in Anaplastic Thyroid Cancer: A Case Series (2019) (21)
- A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). (2013) (20)
- Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. (2017) (20)
- Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. (2020) (20)
- Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy (2014) (20)
- Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle (2015) (20)
- Mucosal melanoma of the head and neck. (2012) (19)
- Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma (2022) (19)
- JAVELIN head and neck 100: A phase 3 trial of avelumab in combination with chemoradiotherapy (CRT) vs CRT for 1st-line treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). (2017) (19)
- Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141 (2017) (19)
- Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. (2018) (19)
- Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. (2016) (18)
- Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer (2003) (18)
- Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. (2017) (18)
- Head and neck cancers. (2011) (18)
- Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. (2003) (18)
- Preoperative pulmonary function tests do not predict outcome after coronary artery bypass. (1997) (18)
- Novel agents for the treatment of mucositis. (2007) (18)
- Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. (2018) (17)
- Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. (2010) (17)
- Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 (2017) (17)
- Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC) (2008) (16)
- Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. (2012) (16)
- Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results (2007) (16)
- Organ preservation for adenoid cystic carcinoma of the larynx. (2013) (16)
- Benefits of radioimmunoguided surgery for pelvic recurrence. (2001) (16)
- Human papillomavirus-associated adenocarcinoma of the base of the tongue. (2013) (16)
- Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options (2014) (16)
- Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). (2015) (15)
- Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (2019) (15)
- Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. (2003) (15)
- Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. (2018) (15)
- Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy (2010) (15)
- Seeking alternative biological therapies: the future of targeted molecular treatment. (2009) (15)
- Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). (2021) (15)
- Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients (2016) (15)
- Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. (2019) (14)
- A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. (2021) (14)
- Thyroid Carcinoma Clinical Practice Guidelines in Oncology (2010) (14)
- Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study (2008) (14)
- Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (14)
- Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. (2016) (14)
- Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. (2005) (14)
- Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States (2020) (14)
- KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. (2019) (14)
- How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer. (2013) (13)
- Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN). (2014) (13)
- IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). (2018) (13)
- Inhibitor-Sensitive FGFR 2 and FGFR 3 Mutations in Lung Squamous Cell Carcinoma (2013) (12)
- LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). (2017) (12)
- Continuous Intravenous Octreotide Treatment for Acute Experimental Pancreatitis (1999) (12)
- Erythema nodosum after smoke inhalation-induced bronchiolitis obliterans organizing pneumonia. (1999) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Induction chemotherapy in head and neck cancer. (2009) (12)
- Population‐based validation of the recursive partitioning analysis–based staging system for oropharyngeal cancer (2016) (12)
- Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. (2022) (12)
- LBA29_PRAFATINIB VERSUS METHOTREXATE (MTX) AS SECOND-LINE TREATMENT FOR PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) WHO PROGRESSED AFTER PLATINUM-BASED THERAPY: PRIMARY EFFICACY RESULTS OF LUX-HEAD & NECK 1, A PHASE III TRIAL (2014) (11)
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial (2020) (11)
- A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. (2019) (11)
- Spontaneous long-term remission in a patient with premature ovarian failure. (2003) (11)
- The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report. (2010) (11)
- A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry. (2018) (11)
- Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy (2007) (10)
- Identification of lymph node metastases in recurrent colorectal cancer. (2000) (10)
- Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. (2015) (10)
- Larynx preservation: a debate worth preserving. (2013) (10)
- Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. (2018) (10)
- POSITRON EMISSION TOMOGRAPHY WITH 18 F-FLUORODEOXYGLUCOSE TO PREDICT PATHOLOGIC RESPONSE AFTER INDUCTION CHEMOTHERAPY AND DEFINITIVE CHEMORADIOTHERAPY IN HEAD AND NECK CANCER (2004) (10)
- Localization of monoclonal antibody CC49 in colonic metastasis from renal cell carcinoma. (1998) (10)
- Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience (2016) (10)
- Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055 (2016) (9)
- Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. (2019) (9)
- Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN). (2017) (9)
- New developments in thyroid cancer. (2013) (9)
- Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714 (2016) (9)
- Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups (2018) (9)
- Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN) (2004) (9)
- Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN). (2013) (9)
- Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. (2020) (9)
- LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy. (2012) (9)
- Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study (2021) (8)
- Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread. (2012) (8)
- Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. (2016) (8)
- Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. (2013) (8)
- IMRT‐based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing (2019) (8)
- Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad) (2021) (8)
- KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. (2015) (8)
- Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study (2022) (8)
- Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations (2019) (7)
- Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC). (2010) (7)
- A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. (2019) (7)
- Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. (2018) (7)
- Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders (2022) (7)
- Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). (2004) (6)
- Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19 (2020) (6)
- Progress and perspectives in chemoprevention of head and neck cancer (2003) (6)
- Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck (2020) (6)
- Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia (2021) (6)
- Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). (2015) (6)
- 2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012 (2015) (5)
- Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer (2003) (5)
- Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 (2022) (5)
- Integrating novel agents into the curative treatment of head and neck cancer (2006) (5)
- Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study (2017) (5)
- Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. (2022) (5)
- Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. (2012) (5)
- Keynote 48: Is it really for everyone? (2020) (5)
- Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer (2006) (5)
- Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation. (1999) (5)
- Locally advanced head and neck cancer. (2013) (5)
- Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review. (2022) (5)
- CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC). (2021) (4)
- immunotherapy of cancerActive8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (4)
- Clinical and translational studies of depsipeptide (romidepsin), a histone deacetylase (HDAC) inhibitor, in patients with squamous cell carcinoma of the head and neck (SCCHN): New York Cancer Consortium Trial P6335 (2007) (4)
- Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 (2022) (4)
- Emerging drugs for head and neck cancer (2006) (4)
- Invited Editorial: What is Environmental Forensics? (2004) (4)
- Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. (2007) (4)
- New frontiers and treatment paradigms for thyroid carcinoma. (2014) (4)
- Aetiology of Paediatric End-stage Renal Failure in Jordan: A Multicentre Study. (2015) (4)
- Everolimus in anaplastic thyroid cancer: A case series. (2018) (4)
- Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study (2008) (4)
- LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS) (2020) (4)
- Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. (2017) (4)
- Biomarkers predictive of response to pembrolizumab in head and neck cancer (2022) (3)
- Neoadjuvant Nivolumab +/- Ipilimumab in Patients with Oral Cavity Cancer (2020) (3)
- Multidisciplinary Management of Head and Neck Cancer (2010) (3)
- Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo (2016) (3)
- Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN) (2005) (3)
- Introduction to Environmental Forensics: B.L. Murphy and R.D. Morrison (Eds.); Academic Press, 2002, 560 pages, hardbound, ISBN 0-12-511355-2, £51.10 (US$ 79.95). (2003) (3)
- Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin (2020) (3)
- Immunologic profiling of adenoid cystic carcinoma (acc) (2015) (3)
- Human Papillomavirus Infection and Oropharyngeal Cancer (2007) (3)
- Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes (2021) (3)
- A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). (2004) (3)
- Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN) (2019) (3)
- Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141 (2018) (3)
- [Photodynamic therapy of nasal basal cell carcinoma]. (2001) (3)
- Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. (2019) (3)
- 1055PNivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141 (2017) (3)
- Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC). (2016) (3)
- O28. Randomized phase II study of concomitant chemoradiation using weekly carboplatin/paclitaxel/concomitant boost radiation with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced head and neck cancer (2009) (3)
- Mucosal Melanoma of the Head and Neck Clinical Practice Guidelines in Oncology (2012) (2)
- Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. (2022) (2)
- A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN). (2018) (2)
- KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC) (2023) (2)
- The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations. (2021) (2)
- Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). (2009) (2)
- The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck (2005) (2)
- Salivary Gland Tumors Treated with Adjuvant Intensity Modulated Radiation with or without Concurrent Chemotherapy: A Recent Experience (2010) (2)
- Oligometastatic Adenoid Cystic Carcinoma: Correlating Tumor Burden and Time to Treatment With Outcomes. (2021) (2)
- Re: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. (2009) (2)
- Effects of intravenous gamma immunoglobulins treatment on severe peritonitis in rats. (2001) (2)
- [Photodynamic therapy for dysphagia due to esophageal carcinoma]. (1999) (2)
- Systemic Immunologic Effects of Definitive Radiation in Head and Neck Cancer (2016) (2)
- Respiratory mechanics and pleural remodelling in pleurodesis induced by barium sulphate (2004) (2)
- Patient Immunosuppression and the Association With Cancer-Specific Outcomes After Treatment of Squamous Cell Carcinoma of the Oropharynx (2016) (2)
- Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II Trial (2021) (2)
- Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma. (2015) (2)
- A phase I/II study of concurrent nab-paclitaxel, carboplatin, and IMRT for locally advanced squamous cancer of the head and neck (LASCCHN). (2012) (2)
- Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. (2014) (2)
- Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1) (2016) (2)
- Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: A randomized sham-controlled study. (2013) (2)
- Deep Learning and Harmonization of Multi-Institutional Data for Automated Gross Tumor and Nodal Segmentation for Oropharyngeal Cancer. (2021) (1)
- Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results (2005) (1)
- The Current Portfolio of Head and Neck Cancer Trials on ClinicalTrials.gov (2018) (1)
- OC-005: Afatinib versus methotrexate in recurrent/metastatic HNSCC after platinum therapy: LUX-head and neck (2015) (1)
- [Photodynamic therapy of gastrointestinal malignant tumors]. (1996) (1)
- 314O_PRSecond-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1) (2015) (1)
- 8502 Long term (Five-year) results of Tax324: A Phase III Trial of Sequential Therapy comparing TPF with PF in Patients with locally advanced squamous cell cancer of the head and neck (2009) (1)
- Clinical Decision-Making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply. (2020) (1)
- Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. (2023) (1)
- Dysphagia Following Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer (2005) (1)
- Medullary thyroid cancer: advances in treatment and management of common adverse events associated with therapy (2012) (1)
- Role of Multi-Targeted Tyrosine Kinase Inhibitors in RAI-Refractory Differentiated Thyroid Cancer. (2014) (1)
- Sequential and Concurrent Chemoradiation: State of the Art. (2015) (1)
- Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension (2023) (1)
- Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) (2020) (1)
- Comprar Multidisciplinary Management Of Head And Neck Cancer | Robert I. Haddad | 9781933864556 | Demos Medical Publishing (2011) (1)
- Medullary Carcinoma Clinical Practice Guidelines in Oncology TM (2010) (1)
- A Phase I/II Study of Concurrent Abraxane, Carboplatin and IMRT for Locally Advanced Squamous Cell Cancer of the Head and Neck (LASCCHN) (2011) (1)
- HPV and survival in patients with oropharyngeal squamous cell cancer of the head and neck (OPC) treated with induction chemotherapy followed by chemoradiotherapy (ST) versus chemoradiotherapy alone (CRT): The Dana-Farber experience. (2012) (1)
- Segmental resection for recurrent carcinoma of the esophagus. (2001) (1)
- Multidisciplinary Approach of Unresectable Head and Neck Cancer (2011) (1)
- Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts). (2016) (1)
- Swallowing function after intensity modulated radiotherapy (IMRT) and chemotherapy for head and neck cancer (2007) (1)
- Abstract CT540: A phase 1 trial of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy with IL-15 superagonist in advanced head and neck cancer: Part 1 results (2022) (1)
- 2440: Re-Irradiation With IMRT for Head and Neck Cancer (2006) (1)
- 341TiPPhase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE (2015) (1)
- Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia (2022) (1)
- 57 Local Control Following Combination Hypofractionated Radiotherapy and Pembrolizumab in a Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients (2019) (0)
- Patient Reported Nausea Associated with Concurrent Weekly Versus Bolus Cisplatin in Patients Treated for Head and Neck Cancer (2019) (0)
- Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). (2004) (0)
- PET/CT imaging in patients with suspected recurrence of pancreatic cancer (2006) (0)
- Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (2023) (0)
- HEAD AND NECK CANCER Locally Advanced Head and Neck Cancer CHAIR (2013) (0)
- Induction Chemotherapy in Locally Adva nced Head a nd Neck C ancer : AN ew St a ndard of C are? (2008) (0)
- 503 Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma (2022) (0)
- Optimizing smoking cessation resource awareness among patients and providers. (2014) (0)
- OrganPreservation forAdenoidCysticCarcinomaof theLarynx (0)
- A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. (2003) (0)
- Choice of Poster Presentations (2020) (0)
- Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. (2014) (0)
- Induction Chemotherapy in Head and Neck Cancer: A Standard of Care (2011) (0)
- S 394 IMRT BASED TREATMENT OF UNKNOWN PRIMARY OF THE HEAD AND NECK : EXCELLENT OUTCOMES AND IMPROVED TOXICITY WITH DECREASED MUCOSAL DOSE (2014) (0)
- Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers (2022) (0)
- Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results. (2018) (0)
- Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: An ongoing pilot, randomized, sham-controlled trial. (2010) (0)
- Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma. (2018) (0)
- Abstract CT165: A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma (2021) (0)
- Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT). (2012) (0)
- 677 A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma (2022) (0)
- Final Safety Results of a Phase 1 Clinical Trial of Afatinib in Combination With Docetaxel and Postoperative Radiation Therapy for High-Risk Squamous Cell Carcinoma of the Head and Neck (2018) (0)
- Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2020) (0)
- Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline (2023) (0)
- Association between Radiation Dose to Organs At risk and Patient Reported Outcome During Treatment for Head and Neck Cancers (2020) (0)
- Radiologic predictors of response to checkpoint inhibitors in advanced head and neck SCC. (2018) (0)
- Retrospective review of patients treated with intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy for locally advanced thyroid cancer: The Dana-Farber experience. (2012) (0)
- Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma (2014) (0)
- Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (2017) (0)
- 1079PLong-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial (2017) (0)
- Predicting PD-L1 Expression using Radiomics in Oropharyngeal Cancer Patients Treated with Definitive Radiation (2018) (0)
- Human Papillomavirus Infection and Oropharynx Cancer (2008) (0)
- Impact of dental insurance coverage on presentation, long-term outcomes, and symptom burden in locally advanced head and neck cancer. (2019) (0)
- Highlights in Head and Neck Cancer. (2017) (0)
- Squamous cell carcinoma of the oral cavity (SCCOC) in young patients: The Dana Farber Cancer Institute experience. (2013) (0)
- Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. (2023) (0)
- Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers. (2021) (0)
- A CME / CE-accredited activity RECENT ADVANCES IN THE TREATMENT OF MALIGNANT LYMPHOMA Updates From the Pan Pacific Lymphoma Conference (2012) (0)
- 2377 : A Phase III, Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients With Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region (2006) (0)
- Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy Versus Concurrent Chemoradiation Therapy Upfront in Locally Advanced Oral Cavity Cancer: Systematic Review and Meta-Analysis of Individual Data (2016) (0)
- miRNA analysis between malignant and benign tissue and circulating exosomes (CE) in patients (pts) with tongue squamous cell carcinoma. (2013) (0)
- Nonsurgical treatment of laryngeal cancer. (2004) (0)
- Head and neck cancer: high-end technology is no guarantee of high-quality care – Authors' reply (2022) (0)
- SP-010: Effect of tumour heterogeneity on treatment selection and failure (2015) (0)
- Avelumab in Combination with Standard of Care Chemoradiotherapy Versus Chemoradiotherapy Alone in Patients with Locally Advanced Scchn: A Randomised, Double-Blind, Phase 3 Trial (2020) (0)
- Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study (2019) (0)
- Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy (2014) (0)
- 691P DNA-based peripheral blood epigenetic immuno-profiling of recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) treated with anti-programmed death (PD)-1 therapy (2022) (0)
- Advances in Collaborative Practice for Patients With Head and Neck Cancers (2017) (0)
- 4 – Cancer of the Head and Neck region (2010) (0)
- Screening for Extranodal Extension with Deep Learning: Evaluation in ECOG-ACRIN E3311, a Randomized De-Escalation Trial for HPV-Associated Oropharyngeal Carcinoma (2022) (0)
- Reply to "Keynote 48: Is it really for everyone?" (2020) (0)
- [Air bags: benefits and risks]. (1996) (0)
- Somatic Frameshift Alterations in Tumor Suppressor Genes May Predict Anti-PD-1/L1 Response in Squamous Cell Carcinoma of the Head and Neck (2018) (0)
- Induction Chemotherapy: Current and Emerging Role in HNSCC (2018) (0)
- Survey of the Adoption of the UICC/AJCC 8th Edition TNM for Head and Neck Cancer: The User’s Initial Experience (2019) (0)
- Safety Results of a Multi-Institutional Phase 1 Clinical Trial of Afatinib in Combination with Docetaxel and Postoperative Radiation Therapy for High-Risk Squamous Cell Carcinoma of the Head and Neck (2017) (0)
- Impact of chemoradiotherapy for locally advanced head and neck cancer on swallowing function (2007) (0)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018) (0)
- Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel With or Without Daily Subcutaneous Amifostine in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (2005) (0)
- Variability in Outcome Based on Type of Concurrent Chemotherapy for Treatment of Squamous Cell Carcinoma of the Oropharynx (2016) (0)
- 1070P Evaluate the role of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era (2018) (0)
- [Surgical treatment for gastric carcinoma--the Japanese versus the western approaches]. (1998) (0)
- Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera. (2010) (0)
- Integrated Clinico-Genomic Analysis of Genetic Ancestry in 1,614 Patients With Cancer Treated With Immune Checkpoint Inhibitors (2022) (0)
- Abstract 452: Salivary HPV cell free DNA levels predict locoregional disease burden and response in oropharyngeal cancer (2019) (0)
- Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). (2004) (0)
- Abstract 2581: Plasma HPV cell free DNA as an earlier predictor of treatment response in advanced oropharyngeal cancer (2018) (0)
- Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC). (2016) (0)
- Human papillomavirus-associated adenocarcinoma of the palatine tonsil--reply. (2014) (0)
- Targeted therapy: Precision comes to life (2020) (0)
- How I Treat Patients with Thyroid Cancer (2013) (0)
- Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients (2019) (0)
- Head and Neck CancersPractice Guidelines in Oncology (2011) (0)
- PIK-ing out an intermediate-risk subgroup in advanced adenoid cystic carcinoma (2020) (0)
- 2378 : Use Of Peripheral Blood Monocytes (PBM) To Define Changes in Gene Expression Associated With Amifostine Treatment and Their Association With Oral Mucositis (OM) in Patients Being Treated With Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck(SCCHN) (2006) (0)
- Abstract S06-02: Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study (2021) (0)
- Immunotherapy and head and neck cancer: Focus on recurrent and metastatic disease (2018) (0)
- Abstract 902: Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer (2011) (0)
- Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly , and patients have a very poor prognosis , ” (2016) (0)
- Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST). (2013) (0)
- A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36) (2022) (0)
- Experimental Design: We performed targeted sequencing of 504 cancer-associated genes on lymph node metastases in 29 patients with cSCC and identified mutations and somatic copy number alterations associated with metastatic cSCC (2015) (0)
- Patterns of Failure After Reirradiation (reRT) With Intensity Modulated Radiation Therapy (IMRT): Not Just a Local Issue (2015) (0)
- Toxicity and Survival After Reirradiation (reRT) With IMRT for Recurrent Squamous Cell Cancer of the Head and Neck (SCCHN) (2014) (0)
- Abstract 4497: Biomarkers of HPV in head and neck squamous cell carcinoma (2012) (0)
- Poster ViewingOutcomes and Patterns of Failure After Postoperative or Definitive Intensity-modulated Radiation Therapy for Oral Cavity Squamous Cell Carcinoma (2017) (0)
- PET/CT imaging in patients with suspected recurrence of pancreatic cancer. (2009) (0)
- Chemotherapy outcomes following immunotherapy failure in advanced squamous cell carcinoma of the head and neck (2020) (0)
- Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor (2022) (0)
- 10:40 AM: Behavior of Oral SCCA in Subjects with Prior Lichen Planus (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert I. Haddad?
Robert I. Haddad is affiliated with the following schools:
